Roche tops cancer reputation rankings as AstraZeneca climbs back
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back…
EPFL’s VirTues AI model maps tumor tissue across cancer types
Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues,…
Roche Backs Full-Year View as First-Half Sales Rise
Roche Holding ROP 0.00%increase; up pointing triangle backed its full-year guidance as its pharmaceuticals division helped drive a…
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced…
Genprex, Roche Collaborate on NSCLC Biomarker Validation
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient…
Pilatus Biosciences expands into Hong Kong
Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary…
FDA approves Pluvicto for PSMA+ metastatic
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced…
How Novartis R&D is advancing the next breakthrough innovations
Novartis is moving earlier, thinking differently, and making deliberate scientific choices to tackle some of medicine’s most complex…
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs.…
CytomX Adds Fuchs With 3+ Decades in Oncology to Board
CytomX Therapeutics (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., a board-certified medical oncologist with…
Meet Colin: A Novartis Scientist Looking for New Breakthroughs
Colin works in San Diego, where we’ve recently broken ground on a new, state-of-the-art global Biomedical Research center…
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads…